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1. Introduction 
Herpes simplex virus type 1 (HSV-1) commonly infects the mucosa and skin epithelial cells, 
and the virus remains latent in sensory neurons mainly in the trigeminal ganglia. Once a 
patient has been infected, the infection continues for life (Hunt, 2011a). Differences in HSV-1 
prevalence have been reported around the world. According to Smith & Robinson (2002), 
the incidence in lower socioeconomic countries is higher. Primary infection, occur mainly in 
infants and young children, infections are usually mild or subclinical. Acute 
gingivoestomatitis is characterized by the appearance of multiple vesicular and ulcerative 
painful lesions in oral mucosa, with inflammation and bleeding of the gums, may also be 
associated with systemic symptoms (Arduino & Porter, 2008). Once the clinical infection 
concludes, the virus reaches peripheral nerves which supply sensation to the skin, migrating 
along the nerve axon to the dorsal root ganglia of the trigeminal or facial nerves and goes 
into latency stage (Esmann, 2001) 
Recurrences of HSV-1 can be triggered by internal and external factors. The reactivation 
mechanism is unknown, the virus begins to replicate within the ganglion and grows down 
the nerves and out into the skin or mucous membranes (Koelle & Corey, 2008). After a 
prodromal of tingling, warmth or itching, the clinical lesion appear (Fatahzadeh & Schwartz 
2007). The recurrence of oral HSV- 1 is developed almost always in the vermilion border of 
the lips but lesions can appear elsewhere around perioral skin (Siegel, 2002).  
Prevention of infection can be achieved by avoiding the physical contact, kissing when the 
lesions are present, touching or using the articles that the patient has used (eating or 
drinking utensils, glasses, or straws). However, in order to prevent the recurrences, the 
control of external factors is recommended; avoiding the exposure to wind burn and 
ultraviolet radiation, using labial protectants and controlling the emotional stress (Paterson 
& Kwong, 2008). 
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On the other hand, internal factors that are related to the recurrence outbreaks such as, 
fever, illness, menstruation, gastrointestinal and respiratory infections, diseases as diabetes 
and hyperthyroidism, fatigue and factors that depress the immune system are difficult to 
control (Siegel, 2002; Paterson & Kwong, 2008). 
Although different clinical assays have been developed in order to assess the efficacy of 
topical or oral antivirals, its effectiveness has not been demonstrated due to the immediate 
and complete termination of viral replication, the restoration of previously infected cells, 
and the inactivation of free virions (Hamuy & Berman 1998). 
There is no treatment that can eradicate herpes virus, even though antiviral medications can 
reduce the frequency, duration, and severity of outbreaks (Emmert, 2006; Siegel, 2002; 
Sprurance, et al., 2003; Sprurance, et al., 2005)  
1.1 Conventional treatment 
According to Hunt (2011b), there are different phases of life cycle of virus; adsorption and 
penetration of the virus in the host cell, and early transcription, in which DNA polymerase, 
DNA binding proteins, thymidine kinase and ribonucleotide reductase are synthesized. 
These proteins are virally-coded, not host-coded enzymes, and therefore potentially weak in 
the virus life cycle, making them promising targets for anti-viral drugs.  
The nucleoside analogues acyclovir, valacyclovir, are phosphorylated initially by viral 
thymidine kinase to eventually form a nucleoside triphosphate, and these molecules inhibit 
herpes simplex virus (HSV-1) polymerase, inhibiting replication of HSV-1 (Balzarini, 1994). 
The best anti-viral drugs are nucleoside analogs such as acyclovir (acycloguanosine). It gets 
into the cell across the plasma membrane as the nucleoside form and is then specifically 
phosphorylated inside the cell by herpes virus thymidine kinase to an active form. The 
advantages of nucleoside analogs are that they are only activated by the virus-infected cell 
and the activated form of the drug is rendered even more specific as a result of the viral 
DNA polymerase being more sensitive to the drug than the host enzyme (Hunt, 2001b) 
In general, acyclovir compounds are safe and effective for treatment of HSV-1 reactivation 
and have good oral bioavailability (Chon & Elliott, 2007). However, topical administration 
of acyclovir at the acute stage of the lesion disease seems to be ineffective. On the other 
hand, its capability to avoid the recurrent episodes produces controversial efficacy (Elish, 
2004; Spruance, et al., 2002). Emmert (2000) suggested that patients with mild and 
infrequent recurrences are not beneficiated with acyclovir treatment. There is general 
consensus that the therapy is most effective when started soon after symptoms occur.  
Rare adverse effects include: coma, seizures, neutropenia, leukopenia, tremor, ataxia, 
encephalopathy, psychotic symptoms, crystalluria, anorexia, fatigue, hepatitis, Stevens-
Johnson syndrome, toxic epidermal necrolysis and/or anaphylaxis (United States Food and 
Drug Administration, FDA, 2011). Also the appearance of virus strains resistant to frequently 
used anti-herpes virus drugs (Greco, et al., 2007 ; Stránská, et al., 2005; Ziyaeyan, et al, 2007)  
1.2 Alternative treatment 
It has been suggested that there are insufficient scientific evidences to support the use of 
alternative medicine in HSV-1 infection. Even though, anecdotal reports of alternative 
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remedies claimed to be beneficial in the treatment of herpes infection, arguing that 
alternative medicine could be beneficial in the treatment of herpes infection through 
enhancing the immune system. The interest in alternative drugs having antiviral effect is 
increasingly, since HSV-1, might develop resistance to commonly used antiviral agents. 
Besides, despite the fact that some patients manifested side effects, the majority of the 
natural remedies did not show a high prevalence of adverse or severe reactions.  
There are a number of natural remedies used in the HSV-1 treatment; some of them have 
been the subject of scientific analysis, demonstrating in vitro and in vivo satisfactory results.  
1.2.1 Some examples of traditional medicine  
In an experimental-placebo study, the application of zinc oxide/glycine cream showed 
shorter duration of cold sore lesions and reduction in overall severity of signs and 
symptoms (Godfrey, et al., 2001). In a pilot study, Femiano, et al. (2005) reported similar 
results and a reduction of number of episodes of herpes labialis. Singh, et al. (2005) in a 
clinical trial, evaluated a combination of L-lysine with a mixture of botanicals and other 
nutrients, with satisfactory results. Since the early 90s, Kümel et al. (1990a, 1991b) explained 
that the zinc ions inactivate virus by inhibition of the virion glycoprotein’s function after a 
nonspecific accumulation of zinc into many virion membrane components, thus inhibiting 
viral adsorption and penetration. Also, Arens & Travis (2000) demonstrated that zinc salts 
inactivated the clinical isolates of HSV in vitro. 
Mårdberg et al., (2001), demonstrated that viruses with mutations at residues Arg129,130, 
Ile142, Arg143,145, Arg145,147, Arg151,155 and Arg155,160 had significantly impaired the 
heparan sulfate (HS) binding. Impairment of the HS-binding activity of glycoprotein C, by 
these mutations had profound consequences for virus attachment and infection of cells in 
which amounts of HS exposed on the cell surface had been reduced. 
Recently Katsuyama et al., (2008) established that Butyroyl-arginine, an arginine derivative, 
strongly inactivates the enveloped virus, as HSV-1. The authors suggest that the ability of 
arginine to bind membranes may be responsible for the inactivation of viruses. Naito et al., 
(2009) also has demonstrated the inhibition of HSV-1 multiplication by ariginine.  
Huleihel & Isanu (2002) reported that propolis could block the cell membrane receptors for 
HSV-1, blocking the penetration of viral particles into the cells and/or inducing the 
intracellular metabolic changes of host cells, which would in turn affect the viral replication 
cycle in vitro.  
Ascorbic acid has been shown to inactivate HSV-1, prevent the virus reactivation, have anti-
inflammatory properties and to enhance the immune function (Gaby, 2006; Hovi, et al., 1995; 
Yoon et al., 2000). Supplementation with flavonoids further increases the effectiveness of 
vitamin C (Terezhalmy, et al., 1978). According to Narayana, et al., (2001), flavonoids 
showed strong antiviral activity against HSV-1. Essential oils of ginger, thyme hyssop and 
sandalwood have been demonstrated to inactivate HSV-1 before it enters into the cells, even 
in acyclovir resistant HSV-1 (Schnitzler, et al., 2007). Melissa officinalis (lemon balm) contains 
rosmarinic acid, phenolic acids and tannins; rosmarinic acid has been reported to show anti-
inflammatory and potent antioxidant action. Schnitzler, et al. (2008), demonstrated that balm 
oil affected the viruses in vitro before adsorption, although the mechanism of action is 
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unclear. They suggest that the balm oil could bind the viral proteins involved in the host 
adsorption and penetration, or damage the virions envelop. Carson, et al. (2006) have 
reported that tea tree oil of Melaleuca alternifolia showed the greatest effect on free virus.  
Surveys of alternative treatment for HSV-1 are difficult to perform, since numerous patients 
are needed the regular contact for long period until the completion of the study. Even so, we 
have applied the vitamin C-supplemented tablet of lignin-carbohydrate complex (LCC) 
prepared from the pine cone of Pinus parviflora Sieb et Zucc., to a sample of HSV-1 patients, 
and investigated its clinical effect for the first time, with satisfactory results (González et al., 
2009). The inhibitory effect of pine cone lignin and ascorbic combination treatment depend 
on antioxidant and immunopotentiating activities of lignin and ascorbic acid (Sakagami, et 
al., 1992).  
The goal of both conventional and alternative treatment is promoting faster healing, 
reduction of symptoms, as well as decreasing the frequency of recurrent episodes. There are 
different phases in the viral cycle, to which the medicaments could be applied, according to 
the properties and mechanism of action of each medication (Fig. 1) 
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Fig. 1. A desirable effect of alternative treatment on HVS-1 virus cycle (Everett, 2006; Frick, 
2003; Mettenleiter, et al., 2006; Newcomb, et al., 2007, Pinnoji, et al, 2007).  
Immune evasion 
HSV evades the immune system through interference with 
MHC class I presentation of antigen on the cell surface 
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2. Functionality of LCC as alternative medicine 
Lignin (polymers of phenylpropenoids), tannin and flavonoid are three major polyphenols 
in the natural kingdom (Table 1). So far, thousands of tannin and flavonoid-related 
compounds have been isolated from the methanol extracts of various plants and their 
complete structures have been elucidated. In contrast, lignins, extracted with alkaline 
solution, have been bound to polysaccharides (composed of glucose, arabinose, mannose, 
galactose, fucose, or uronic acids) to form lignin-carbohydrate complex (LCC) (Fig. 2).  
 
  Component unit MW (kDa) 
Tannin Hydrolysable 
Tannin 
Esters of gallic acid and its oxidative derivatives 
with glucose or related sugars 
0.5~4 
   
 Condensed 
tannin 
Flavan oligomers or polymers where their 
constituent monomeric flavans are connected 
mainly by C-4 – C-8 or C-4 – C-6 linkages 
0.3~2 
   
Flavonoid Oxygen containing cyclic structure between two 
benzene rings 
0.3~1 
   
Lignin carbohydrate 
complex (LCC) 
Complex of phenylpropenoid polymers and 
polysaccharide 
10~200 
Table 1. Representative polyphenols present in the natural kingdom. 
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Fig. 2. Structure and function of lignin-carbohydrate complex (LCC) 
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This structural complexity of LCC has made it difficult to elucidate its complete structure. 
Varying the ratio of polysaccharide to phenylpropenoid polymer produces heterogeneity in 
the acidity, water-solubility, ethanol-insolubility, and molecular weight of LCC that might 
strongly affect its antiviral potency (Sakagami, et al., 2005, 2010b). However, this possibility 
has not been tested yet by any investigators. LCC was recoverable at much higher yield 
from the alkaline solution, in contrast to tannins and flavonoids (Fig. 3). The higher yield of 
LCC is very convenient for the mass-production in the factory. 
2.1 Identification of LCC as an active antitumor principle of pine cone extract 
We have paid attention to the folklore that intake of the hot water extract of pine cone of 
Pinus parviflora Sieb. et Zucc is effective for gastroenterological tumors. We isolated various 
polysaccharide fractions (Fig. 3), and investigated their antitumor activity against ascites 
sarcoma-180 cells (Sakagami, et al., 1987).  
Pine cone (100%)
EtOH wash
Hot water extraction
Extract                                                         Residue
EtOH precipitation                                                 1%NaOH extraction 
DEAE cellulose column                                           pH adjusted to 5
Flow through fr.           Adsorbed fr.                       ppt sup
Fr. VI                        ×1 EtOH
Fr. I                                                        (0.14%)
(0.10%)     Fr. II       Fr. III      Fr. IV     Fr. V          ppt sup
(0.61%)  (0.01%) (0.004%) (0.14%)                Fr. VII                      ×2 EtOH
(0.88%)        
ppt sup
Fr. VIII                 ×5 EtOH
(0.11%)
ppt sup
Fr. IX
(0.74%)
Anti-tumor activity against mouse ascites tumor (T/C%):
Fr. VII (282) > Fr. VI (227)> Fr. XI (198) > Fr. III (175) > Fr. V (172)
> Fr. VIII (166) > Fr. IV (151) > Fr. II (118) > Fr. I (96)
 
Fig. 3. Fractional preparation of LCC fractions from Pinus parviflora Sieb. et Zucc. Cited from 
Sakagami et al. (1987), with permission. 
Pine cone was treated with ethanol to remove the sticky resin that contains cytotoxic 
substances, and then extracted with hot-water and then alkaline solution (1% NaOH). 
Polysaccharides in the hot water extract were precipitated by 86% ethanol, and then applied 
to DEAE-cellulose column chromatography. Neutral polysaccharide fraction (Fr. I) passed 
through the column, and then acidic polysaccharide fractions (Fr. II and III) rich in uronic 
acid were eluted from DEAE cellulose column chromatography with 0.5 and 2 M NaCl, 
respectively. The most acidic polysaccharides (Fr. VI and Fr. V) were eluted with 0.15M 
NaOH. The anti-tumor activity [evaluated by the survival ratio of treated group to control 
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group (T/C%)] increased with the acidity: Fr. I (T/C=98%) < Fr. II (T/C=118%) < Fr. III 
(T/C=175%), Fr. IV (T/C=151 %) < Fr. V (T/C=172%) (Sakagami, et al., 1987). Higher anti-
tumor activity was recovered by extraction with 1%NaOH, precipitated by acidification (pH 
5) (Fr. VI) (T/C=227%), and also by ethanol precipitation (Fr. VII) (T/C=282%).  
The most active acidic polysaccharide (IV) was subjected to spectral analysis, and identified 
as lignin-carbohydrate complex (LCC), based on the following evidences (Sakagami, et al., 
1989). (i) UV absorption spectra：minimum absorption at 260 nm, maximum absorption at 
280 nm, broad maximum absorption at 500 nm. (ii) IR spectra: hydroxyl group with 
hydrogen bonding (3400 cm-1), aliphatic C-H (2700 cm-1), carbonyl group conjugated to π-
electron system (1700 ~ 1600 cm-1), aromatic double bond (1600, 1500 cm-1), C-O expansion 
and contraction (1400 ~ 1000 cm-1), no ester bonding.(iii) ESR: one strong signal at g=2.003 
under solid state at room temperature. Signal intensity was significantly reduced by 
oxidation and reduction.(iv) 1H-NMR： When measured in 0.2%NaOD-D2O, the presence of 
hydrogens in aromatic CH (δ6.5~7.5 ppm), >C=C< (δ4.5~5.5 ppm) and –O-CH-CH (δ3.0 ~ 
4.0 ppm) was suggested.  When the sample was acetylated by pyridine-acetic acid 
anhydride and dissolved in CDCl3, the presence of acetyl group bound to phenolic OH (δ 2.3 
ppm) or bound to alcoholic OH (δ 2.1 ppm) was confirmed. (v) Thin layer chromatography: 
Rf value of Fr. VI was the same with that of commercial alkali-lignin in various solvent 
systems (Table 2). 
 
UV Absorption spectra absorption peak at 260, 280, 500 nm (broad) 
IR spectra 3400, 2700, 1700~1600, 1600, 1500, 1400~1000 cm-1 
ESR spectra g=2.003 (strong signal) 
1H-NMR spectra δ6.5~7.5, 4.5~5.5, 3.0~4.0 ppm 
TLC The same Rf value with alkali-lignin 
Elementary analysis C (43.21%), H (3.96%), N (2.61%), S (not detectable) 
Neutral sugar/uronic acid 11.0%/1.7% 
Composition of neutral sugar Gal (44.7%), Glc (26.9%), Man (19.0%), Fuc (9.4%) 
Molecular weight  10 kDa on gel filtration chromatography  
Table 2. Identification of Fr. IV from pine cone of Pinus parviflora Sieb. et Zucc. as LCC, 
based on chemical analyses. Cited from Sakagami et al. (1987), with permission.  
2.2 Distribution of LCC in the natural kingdom 
Frs. VI and VII, prepared from the pine cones of Pinus parviflora Sieb. and Zucc. (T/C=227, 
247%) showed higher antitumor activity in mice, than those prepared from Pinus densiflora 
Sieb. et Zucc (T/C=155, 245%), Pinus thunbergii Parl. (T/C=218, 191%), Pinus elliottii var. 
Elliotti (T/C=170, 217%), Pinus taeda L. (T/C=196, 179%), Pinus caribaea var. Hondurenses 
(T/C=114, 147%), Pinus sylvestris L. (T/C=180, 135%), or the pine seed shells of Pinus 
parviflora Sieb. et Zucc. (T/C=194. 220%), and Pinus armandii Franch (T/C=125%). 
Furthermore, the yields of Frs. VI and VII, prepared from Pinus parviflora Sieb. et Zucc. (0.51, 
0.91%) were much higher than those from other pine cone sources [0.19±0.18 (0.001~0.48), 
0.31±0.16 (0.06~0.48) %] (Harada, et al., 1988). These data suggest that acidic polysaccharides 
(Frs. VI and VII) are responsible for the legendary antitumor potential of the pine cone of 
Pinus parviflora Sieb. et Zucc.  
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LCCs from pine cone from Pinus parviflora Sieb et Zucc., and Pinus elliottii var. Elliotti [SI 
(selectivity index for measuring anti-HIV activity) =14, 28), bark of Erythroxylum catuaba Arr. 
Cam. (SI=43) (Manabe, et al., 1992), husk and mass of Theobroma cacao (SI= 311, 46) 
(Sakagami et al., 2008, 2011) and cultured extract of Lentinus edodes mycelia (LEM) (SI=>94) 
(Kawano et al. 2010) and mulberry juice (SI=7) (Sakagami et al., 2007, 2010b; Sakagami & 
Watanabe, 2011) showed higher anti-HIV activity than lower molecular weight polyphenols, 
such as tannins (SI=1-11) (Nakashima, et al., 1992b) and flavonoids (SI=1) (Fukai, et al., 
2000), and natural and chemically modified glucans [N,N-dimethylaminoethyl paramylon, 
N,N-diethylaminoethyl paramylon, 2-hydroxy-3-trimethylammoniopropyl paramylon, 
sodium caroboxymethyl paramylon, carboxymethyl-TAK) (SI=1) except for sulfated 
polysaccharide (such as paramylon sulfate and dextran sulfate) (Koizumi, et al., 1993). 
Limited digestion of lignin structure by NaClO2 resulted in significant loss of anti-HIV 
activity (from SI=14 to 3), whereas removal of the monosaccharide residues by acid-
catalyzed hydrolysis did not significantly affect the anti-HIV activity (from SI= 14 to 13) (Lai 
et al., 1992) suggesting that that phenylpropenoid polymer, but not sugar moiety, is 
important for anti-HIV activity. This was confirmed by our finding that dehydrogenation 
polymers of phenylpropenoids without carbohydrate showed generally higher anti-HIV 
activity (SI=105) than LCCs (Nakashima, et al., 1992a). On the other hand, phenylpropenoid 
monomers (p-coumaric acid, ferulic acid, caffeic acid) were inactive, suggesting the 
importance of highly polymerized structure (Nakashima, et al., 1992a). The mechanism of 
anti-HIV activity induction has been suggested to be mediated by the inhibition of HIV 
adsorption to the cells (Nakashima, et al., 1992a). In vitro, LCCs have also been reported to 
inhibit the HIV-1 reverse transcriptase activity (Lai, et al., 1990, 1992) and HIV-1 protease 
activity (Ichimura, et al., 1999).  
2.3 Anti-HSV activity in vitro 
2.3.1 Inhibition of HSV-1 infection by Fr. VI 
Inhibition of HSV infection was determined by plaque assay. Cells were inoculated with 
HSV-1 (200-400 plaques per well (3.5 cm diameter) 2 days after infection. Fr. VI showed 
potent anti-HSV-1 activity. Addition of Fr. VI during and after adsorption significantly 
reduced the number of plaques without affecting the morphology of the CV-1 cells. The 
plaque formation of HSV-1 was significantly inhibited by Fr. VI at a concentration of more 
than 0.1 g/ml and completely inhibited by Fr. VI at more than 10 g/ml (Fig. 4) 
(Fukuchi, et al., 1989a). Fr. VI inhibited the cytopathic effect of two different HSV-1 strains 
(HF and F) and HSV-2 strain G on two samples of cultured monkey kidney cells (CV-1 
and Vero) and one sample of human adenocarcinoma cells (A-549). From the dose-
response curves, the doses of Fr. VI that inhibited plaque formation by 50% (50% effective 
dose) in these cells were calculated to be 0.1-0.3 g/ml (Fig. 4). When Fr. VI was adsorbed 
on and eluted from Sephadex LH-60, anti-HIV activity was slightly enhanced (Fr. VIb in 
Fig. 4). 
Neither the growth rate nor the saturation density of CV-1 cells was significantly affected by 
up to 100 g/ml of Fr. VI (Fig. 5). This indicates that the anti-HSV-1 effect of Fr. VI was not 
merely due to toxicity for the host cell. 
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Fig. 4. Inhibition of HSV-1 plaque formation by Fr. VI and Fr. VIb in various cultured cells. 
The indicated doses of Fr. VI were added to the CV-1 cells at the time of infection with HSV-
1 (HF) (●) or HSV-1 (F) (○), to the Vero cells at the time of infection with herpes virus 
simplex type 2 (G) (■), or to the A549 cells at the time of infection with HSV-1 (HF) (□). The 
CV-1 cells were also infected with HSV-1 (HF) in the presence of the indicated doses of Fr. 
VIb (▲). After washing with DME, these infected cells were overlaid with agarose, further 
incubated for 2 days in the presence of the same amounts of Fr. VI or Fr. VIb, and the 
number of plaques was then determined. Each value represents mean of triplicate 
determinations. Cited from Fukuchi, et al., (1989a), with permission. 
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Fig. 5. Effect of Fr. VI on the growth of CV-1 cells. Each value represents mean of triplicate 
assays. Cited from Fukuchi, et al., (1989a), with permission.  
2.3.2 Anti-HSV activity of LCCs from other plants, natural and chemically modified 
polysaccharides 
Neutral polysaccharide (Fr. I) and uronic acid-rich polysaccharide (Fr. II) from pine cone 
extract of Pinus parviflora Sieb. et Zucc. had no anti-HSV activity at 10 g/ml. Similarly, 
popular antitumor polysaccharides, such as paramylon, PSK, Schizophyllan, and chemically 
modified glucans (N,N-dimethylaminoethylparamylon, sodium carboxymethylparamylon, 
sodium paramylon sulfate, carboxymethyl TAK) were all inactive at 10 g/ml. On the other 
hand, Fr. V tightly bound to DEAE-cellulose chromatography, and four LCC fractions (Frs. 
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VI-IX) almost completely inhibited the HSV-infection at 10 g/ml (Table 3). LCC fractions 
(Frs. VI, VII) obtained from cones of other Japanese pine trees (Pinus densiflora Sieb. et Zucc., 
Pinus thunbergii Parl.), three Brazilian pine trees (Pinus elliottii var. Elliottii, Pinus taeda L., 
Pinus caribaea var. Hondurensus) and one Finnish pine tree (Pinus sylvestris L.), and from the 
seed shells of Pinus parviflora Sieb. et Zucc., and Pinus armandii Franch, also showed potent 
anti-HSV activity (Table 3).  
 
Sample Fr. 
No. of 
plaques 
% of 
inhibition 
Neutral polysaccharide from cone of Pinus parviflora Sieb et Zucc. I 310 0 
Acidic polysaccharide from cone of Pinus parviflora Sieb et Zucc. II 321 0 
LCCs from pine cone of Pinus parviflora Sieb et Zucc.             V 0 100 
   VI 0 100 
             VII 33 89 
             VIII 0 100 
  IX 0 100 
LCCs from cone of Pinus densiflora Sieb. et Zucc. VI 0 100 
 VII 9 97 
LCCs from cone of Pinus thunbergii Parl. VI 0 100 
 VII 0 100 
LCCs from cone of Pinus elliottii var. Elliottii VI 2 99 
 VII 0 100 
LCCs from cone of Pinus taeda L. VI 0 100 
 VII 12 96 
LCCs from cone of Pinus caribaea var. Hondurenses VI 0 100 
 VII 0 100 
LCCs from cone of Pinus sylvestris L. VI 0 100 
 VII 0 100 
LCCs from seed shell of Pinus parviflora Sieb et. Zucc. VI 0 100 
  VII 0 100 
LCC from seed shell of Pinus armandii Franch VI 0 100 
Paramylon 310 0 
PSK 320 0 
Schizophyllan 325 0 
N,N-dimethyaminoethylparamylon 306 0 
Sodium carboxymethylparamylon 312 0 
Sodium paramylon sulfate 299 2 
Carboxymethyl-TAK 320 0 
Alkali-lignin 0 100 
Tannic acid 0 100 
Saline (control) 305  
Table 3. Anti-HSV activity of LCCs, natural and synthetic polysaccharides, added at 10 
g/ml. Each value represents mean of triplicate assays. Cited from Fukuchi, et al., (1989a), 
with permission. 
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2.3.3 Interference by Fr. VI of HSV-1 cellular adsorption 
To determine the point of inhibition of HSV-1 infection, cells were treated with Fr. VI at 
various times before and after HSV-1 infection. Table 4 shows that: (i) no protective effect 
was observed when Fr. VI was not present in the adsorption medium, and (ii) pretreatment 
of the cells with Fr. VI for 6 days did not decrease the number of plaques.  
 
Fr. VI (g/ml)   
Before adsorption During adsorption After adsorption No. of plaques % of inhibition 
0 0 0 229 
10 (6 days) 0 0 204 11 
0 10 0 0 100 
0 0 10 230 0 
10 (6 days) 0 10 188 18 
Table 4. Dependence of anti-HSV activity induction by Fr. VI on treatment schedule. CV-1 
cells were infected with HSV-1 strain HF. Fr. VI was added at the indicated stages. Each 
value represents mean of three separate assays. Cited from Fukuchi, et al., (1989a), with 
permission. 
The results suggest that the protective effect of Fr. VI might be caused by its inhibition of 
virus adsorption. To test this possibility, the CV-1 cells were incubated with higher 
concentrations of radiolabeled virus particles (20,000 PFU) in the presence of Fr. VI, and the 
cell-bound radioactivity was measured. Table 5 shows Fr. VI at 10 g/ml significantly 
inhibited the binding of the radiolabeled virus particles, even when the cells were incubated 
with higher concentrations of virus. Lignin similarly inhibited virus adsorption, but its effect 
was slightly lower than that of Fr. VI (Table 5). 
 
  Cell-bound radioactivity 
Sample Dose (g/ml) cpm % of inhibition 
Fr. VI 0 3007168 
 10 438230 85 
Lignin 0 5367184 
 10 2774491 48 
 100 19353 96 
Table 5. Inhibition of radiolabeled virus adsorption by Fr. VI and lignin. CV-1 cells were 
incubated for 1 hour at 37C with the radioactive virus particle equivalent to 60,000 cpm 
(20,000 PFU/well) in the absence or presence of the indicated amounts of Fr. VI or lignin, 
and the cell-bound radioactivity was then determined. Each value represents mean  S.D. of 
triplicate assays. Cited from Fukuchi, et al., (1989a), with permission. 
We next investigated the effect of Fr. VI on virus penetration. Cells were first adsorbed for 
1~2 hours with virus (200-400 PFU/well) at 4C, a condition that allows virus adsorption 
but not virus penetration. The cells were treated with Fr. VI and the temperature was then 
raised to 37C to initiate virus penetration. Fr. VI (1 g/ml) did not inhibit plaque formation 
after completion of virus adsorption (data not shown). From the results, it was concluded 
that Fr. VI inhibits virus adsorption on target cells, but does not inhibit virus penetration. 
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We have previously reported that LCC also inhibited the adsorption of HIV to the cells 
(Nakashima, et al., 1992a, 1992b). 
Recently, carboxylated lignins, synthesized using 4-hydroxy cinnamic acid scaffold by 
enzymatic oxidative coupling inhibited the entry of HSV-1 entry into the cells (Thakkar et 
al., 2010). Sulfated LCL (PPS-2b) (MW8500) also showed anti-HSV activity possibly by 
inhibiting the viral binding and penetration into host cells. Prunella cream formulated with 
a semi-purified fraction significantly reduced the skin lesion and mortality induced by HSV-
1 infection in Guinea pigs (Zhang et al., 2007) The anti-HSV activity of sulfated lignins 
depended on their molecular weight, with the maximum at 39.4 kDa (Raghuraman et al. 
2007). 
2.4 Clinical effect of LCC-ascorbic acid tablet 
The combination of alternative products can provide an effective therapy. To evaluate anti- 
HSV-1 activity of a pine cone LCC and ascorbic acid treatment, a clinical pilot study was 
carried out. We have modified the extraction method of LCC to achieve the mass production 
at the factory level (Fig. 6). Each LCC-ascorbic acid tablet contained a mixture of 50 mg pine 
cone extract powder JS, 50 mg ascorbic acid, 83 mg maltitol, 13 mg potato starch and 13 mg 
calcium stearate. 
Pine cone (100%)
Hot water wash
1% NaOH extraction
Extract                Residue
Neutralized with HCl
Concentrated with reduced pressure
EtOH treatment
ppt
Dissolved in hot water to remove EtOH
Concentrated
Mixed with dextrin
Dried
Crude LCC fraction
(50%)  
Fig. 6. Modified method for mass production of LCC at the factory level. 
A pilot clinical study with pine cone lignin and ascorbic acid complex treatment against 
HSV-1-patients was carried out to evaluate the reduction of the duration with lesions, and 
the decrease of symptoms. A convenience sample of forty eight healthy patients of both 
genders between 4 and 61 years old (mean: 31±16.12 years), with active lesions of HSV-1, 
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took part in the study. The patients were classified into the prodromic (16 patients), erytema 
(11 patients), papule edema (1 patient), vesicle/pustule (13 patients) and ulcer stages (7 
patients). One mg of LCC-ascorbic acid tablet or solution was orally administered three times 
daily for a month. Clinical evaluations were made at least three times a week during the two 
first weeks after the onset and every six months during the subsequent year to identify 
recurrence episodes. The patients who began the LCC-ascorbic acid treatment within the first 
48 hours did not develop HSV-1 characteristic lesions, whereas those patients who began the 
treatment later experienced a shorter duration of cold sore lesions and a decrease in the 
symptoms compared with previous episodes. The majority of the patients reported a 
reduction in the severity of symptoms and a reduction in the recurrence episodes after the 
LCC-ascorbic acid treatment compared with previous episodes, suggesting its possible 
applicability for the prevention and treatment of HSV-1 infection. Figs. 7, 8 and 9. 
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Fig. 7. Previous and new duration of lesions after pine cone ascorbic acid treatment. A 
significant difference in the duration of lesions was found between before and after 
treatment. Usual duration is based on patient report. Student’s t 4.202 p =0.001. Cited from 
González et al. (2009) with permission. 
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Fig. 8. Symptoms reduction according to the day of starting pine cone lignin and ascorbic 
acid complex treatment after onset.  Symptoms were reduced notoriously when the 
treatment was taken in the first 48 h. after onset Kendall's Tau-b 0.456 p= 0.001. Cited from 
González, et al., (2009) with permission. 
ration of sympto  ( ) 
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Fig. 9. Recurrence rate after pine cone lignin ascorbic acid complex treatment. Cited from 
González et al. (2009) with permission. 
Majority of the patients reported the reduction in the severity of symptoms and in the 
recurrent episodes. This pilot study suggests possible applicability of LCC-vitamin C tablet 
for the prevention and treatment of HSV-1 infection (González, et al., 2009). However, it is 
not clear whether this clinical effect is due to the antiviral action of LCC itself or due to the 
combination effect of LCC + vitamin C.  
We found significant differences between the usual and current duration after the pine cone 
lignin and ascorbic acid combination treatment and differences in the reduction of 
symptoms, taking into account the historical data provided by the patients. However, the 
small number of patients and the lack of a control group limited our ability to generalize the 
results to a larger population. To evaluate the effectiveness of pine cone lignin and ascorbic 
acid combination treatment, subsequent double-blind randomized controlled clinical trials 
must be done in a representative sample of patients who suffer from recurrent HSV-1. 
2.5 Clinical effect of LCC tablet without vitamin C 
In order to evaluate the effect of LCC obtained from pine " Pinus parviflora Sieb et Zucc.” 
without ascorbic acid, on the treatment of infection by HSV type I, we already started a 
cross-sectional study on a sample of the patients, from the School of Dentistry of the Mexico 
State University. It has been planned to develop a double blind randomized clinical study in 
a larger, heterogeneous sample of captive population, incorporating students, professors 
and working personal of the Schools of Health Sciences of the University, the study will be 
carried out during three years. 
Patients aged 18 or more who gave informed consent will enter into the study; they will be 
initially identified through an interview, and they will be asked to answer a questionnaire 
that includes signs and symptoms, the triggers and the treatments used. The patients will be 
randomized for treatment or placebo. No other antiviral drugs will be permitted during the 
study 
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The patients will be seen as soon as possible after the start of the outbreaks. The tablets will 
be delivered to patients with the instruction of taking a tablet 3 times a day for 30 days. The 
patients will be seen daily or at least three times during the episode until the complete 
healing had occurred. Any possible adverse effects will be recorded. When a recurrence 
occurs, the patients will repeat the treatment as previously described. The placebo group 
treatment protocol will be the same, but tablets without LCC will be administrated. 
Until now we have identified 18 patients with a history of infection by HSV-1, who accepted 
to participate in the study, they signed the informed consent and answered the 
questionnaire. Among them only six patients have attended the clinic at the early stage of 
the disease, we carried out a clinical follow-up of patients to register the evolution of the 
disease (Table 6). In general the patients reported a reduction of the duration of the lesions 
and of the symptoms, according to their previous experience (Fig. 10-14). 
One patient presented a light rash at the tenth day of LCC treatment. This disappeared 
without treatment, once the patient suspended the treatment. At present, it is not clear 
whether the reaction could be related with the LCC treatment. Alternatively, this may 
suggest that the combination of LCC and vitamin C is necessary to reduce such incidence.  
 
Patient Date of 
initiation of 
treatment 
Decrease of 
symptoms
Edema Eritema Vesicle Erosion Seudomebrane Scab Gender/Age 
Female Male 
49  
Mar, 
31 
Apr, 
03 
Mar, 
31 
- - - 
Apr, 
06 
Apr, 
06 
 23 
Mar, 
01 
Mar, 
02 
- 
Mar, 
01 
- 
Mar, 
08 
Mar, 
09 
Mar,  
09 
 21 
July, 
10 
July, 
10 
- 
July, 
11 
July, 
12 
July , 
12 
July, 
13 
July, 
13 
53  
Feb,  
02 
Feb,  
02 
Feb,  
02 
Feb,  
03 
Feb,  
04 
Feb,  
04 
Feb, 
05 
Feb,  
05 
57  
Jan 
 10 
Jan 
 10 
- - 
Jan 
12 
Jan 
12 
Jan 
13 
Jan 
14 
 24* 
Mar, 
29 
Mar, 
30 
Mar, 
29 
Mar,  
31 
Apr, 
 01 
Apr, 
01 
Apr, 
02 
Apr, 
02 
*The patient presented a light skin rash. 
Table 6. Evolution of the lesions of HSV-1 in five patients treated with LCC tablet without 
vitamin C. 
 
  
Fig. 10. Male 21 years old, a) Vesicles, b) Scab early stage  
a b 
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Fig. 11. Male 24 years old, a) Ulcerative stage, c) Seudomembrane stage, d) Skin rash 
 
   
Fig. 12. Male, 25 years old. a) Erosion stage, b) Late scab stage, c) Complete healthy stage 
 
  
Fig. 13. Female 57 years old, a) Ulcerative stage, b) Scab early stage  
 
 
Fig. 14. Female 53 years old, a) Vesicle stage, b) Ulcerative stage, b) Seudomembrane stage 
Fig. 10-14. Stages in the evolution of HSV-1 lesions in patients who received treatment with 
LCC. Only representative photographs were shown. 
a 
b c 
a b c 
a 
b 
a
b 
c 
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3. Conclusion 
We have demonstrated that LCC from pine cone of Pinus parviflora Sieb. Zucc. showed anti-
HSV activity in vitro, by inhibiting the viral adsorption to the cells. LCC shows broad 
antiviral spectrum. LCC exhibited high affinity with influenza virus, and in contact to LCC, 
influenza virus rapidly lose the virulence (Sakagami, et al., 1992). LCC showed much higher 
anti-HIV activity than tannins (Nakashima, et al., 1992a, 1992b), whereas both LCC and 
tannins showed potent anti-HSV activity (Fukuchi, et al., 1989a, 1989b). Since virus is one of 
major risk factor of oral cavity cancer (Sakagami, 2010a), anti-viral action of LCC may 
reduce the incidence of virus-triggered diseases such as cancer. 
LCC shows also immunopotentiating activity. Administration with LCC induced antitumor, 
antimicrobial and anti-parasite activity, and enhanced the endogenous TNF production. At 
present, the receptors for LCC have not been identified. Recently, we have found LCC 
fraction isolated from Lentinus edodes mycelia extract (Fr4) enhanced the expression of 
dectin-2 (4.2-fold) and toll-like receptor (TLR)-2 (2.5-fold) prominently, but only slightly 
modified the expression of dectin-1 (0.8-fold), complement receptor 3 (0.9-fold), TLR1, 3, 4, 9 
and 13 (0.8- to 1.7-fold), spleen tyrosine kinase (Syk)b, zeta-chain (TCR) associated protein 
kinase 70kDa (Zap70), Janus tyrosine kinase (Jak)2 (1.0- to 1.2-fold), nuclear factor (Nf)кb1, 
NFкb2, reticuloendotheliosis viral oncogene homolog (Rel)a, Relb (1.0- to 1.6-fold), Nfкbia, 
Nfкbib, Nfкbie, Nfкbi12 Nfкbiz (0.8- to 2.3-fold). On the other hand, LPS did not affect the 
expression of dectin-2 nor TLR-2. These data suggest the significant role of the activation of 
the dectin-2 signaling pathway in the action of LCC on macrophages (Kushida, et al., 2011). 
Identification of dectin-2 as LCC receptor awaits further confirmation with siRNA and gene 
over expression experiments. 
The other intriguing property of LCC is the synergy with vitamin C. Ascorbate derivatives 
that produced the doublet signal of ascorbate radical (sodium-L-ascorbate, L-ascorbic acid, D-
isoascorbic acid, 6-β-D-galactosyl-L-ascorbate, sodium 5,6-benzylidene-L-ascorbate) induced 
apoptosis in HL-60 cells, whereas ascorbate derivatives that did not produce radicals (L-
ascorbic acid-2-phosphate magnesium salt, L-ascorbic acid 2-sulfate and dehydroascorbic 
acid) did not induce apoptosis (Sakagami, et al., 1996a, 1996b). High concentrations of LCC 
from the pine cone of Pinus parviflola Sieb et Zucc., pine cone of Pinus elliottii var. Elliotti, leaf 
of Ceriops decandra (Griff.) Ding Hou and, thorn apple of Crataegu Cuneata Sieb. et Zucc 
enhanced the radical intensity and cytotoxicity of sodium ascorbate. On the other hand, 
lower concentrations of LCC stimulated the superoxide anion (O2-), hydroxyl radical and 
1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity of sodium ascorbate 
(Sakagami et al., 2000, 2005, 2008) . This suggests the possible application of LCC as 
stimulator of vitamin C action, especially in the field of UV protection and anti-aging 
research. 
Solvent fractionation of alkaline extract of the leaves of Sasa senanensis Rehder (SE) 
demonstrated that (i) chlorophyllin in SE was recovered from the water layer, that contains 
majority of compounds (more than 81%) and inhibited the NO production by macrophages 
more potently than other n-hexane, diethyl ether and ethylacetate layers (Sakagami, et al., 
2010c). Three-dimensional HPLC analysis demonstrated that the majority of SE components 
are recovered from one major peak. Furthermore, LCC isolated from SE showed the unique 
greenish color of chlorophyllin (absorption maximum = 452 nm) (Sakagami, et al., 2010c). 
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These data strongly suggest the possible association of chlorophyllin with LCC in the native 
state or during extraction with alkaline solutions. Biological significance of such association 
remains to be investigated. 
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